Revealed: A Real Solution for Depression?
Depression is the leading cause of disability worldwide. For nearly 100 million people… there's no known solution. That's right. Nearly one-third of the world's 322 million people suffering from depression have no existing treatment. But that's all about to change.
Here's how you could capitalize off this

CLIN Insider Trading (Clinigen Group)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £12,080
Insider Selling (Last 12 Months): GBX 0

Clinigen Group Insider Trading History Chart

Clinigen Group Share Price & Price History

GBX 628
▼ -9 (-1.41%)
As of 06/22/2021 05:35 PM ET
Days: 30 | 90 | 365
Invest In Psychedelic Therapy?
Psychedelic Therapy Clinics are popping up all over LA and Arizona. Some of them charge up to $2,000 for a full treatment... this is an emerging trend every investor should consider.
Tell Me More About Psychedelic Therapy

Clinigen Group Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/27/2020Ian James NicholsonInsiderBuy2,000GBX 604£12,080
3/23/2020Shaun Edward ChiltonInsiderBuy10,000GBX 416£41,600
9/19/2019Nick KeherInsiderBuy3,900GBX 893£34,827
See Full Table
Clinigen Group logo
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Read More on Clinigen Group

Today's Range

Now: GBX 628
621
640

50 Day Range

MA: GBX 800.13
581
856.50

52 Week Range

Now: GBX 628
554
891.79

Volume

323,923 shs

Average Volume

562,781 shs

Market Capitalization

£835.42 million

P/E Ratio

64.74

Dividend Yield

1.19%

Beta

N/A

Who are the company insiders with the largest holdings of Clinigen Group?

Clinigen Group's top insider shareholders include:
  1. Ian James Nicholson (Insider)
  2. Nick Keher (Insider)
  3. Shaun Edward Chilton (Insider)
Is this Seattle Penny Pot Stock a Potential Blockbuster?
A small, rapidly expanding Seattle cannabis company is gaining attention from investors. Founded by two cannabis veterans, the company has increased sales 8-fold and is looking to double sales again in the next two years. Now selling for less than $1 per share, this is an opportunity to acquire thousands of shares – a potential windfall.
Get Free Report on #1 Cannabis Pick for 2021